Filing Flows › Covista (CVSA) › Q4 FY26 › vs Q3 FY26
Covista (CVSA) Q4 FY26 vs Q3 FY26 (quarter over quarter)
Covista's revenue rose $14.4M (+3%) from $487M in Q3 FY26 to $501M in Q4 FY26. The biggest changes: Walden +$24.3M (+13%); Chamberlain −$6.7M (-3%); Medical and Veterinary −$3.2M (-3%). Operating margin 19.0% against 18.8% (+0.3 pts).
Covista, Q4 FY26: revenue $501M (+10% year over year), operating margin 19.0%, net earnings $71.7M, operating cash flow $124M. The chart draws each line against Q3 FY26, the increases inside each band.
Margins
| Q4 FY26 | Q3 FY26 | Change | |
|---|---|---|---|
| Operating margin | 19.0% | 18.8% | +0.3 pts |
| Net margin | 14.3% | 8.5% | +5.8 pts |
| Free cash flow margin | 19.4% | 34.1% | -14.7 pts |
Every line
| Line | Q4 FY26 | Q3 FY26 | Change | % |
|---|---|---|---|---|
| Walden | $211M | $187M | $24.3M | +13% |
| Chamberlain | $190M | $197M | −$6.7M | -3% |
| Medical and Veterinary | $100M | $103M | −$3.2M | -3% |
| Revenue | $501M | $487M | $14.4M | +3% |
| Operating profit | $95.4M | $91.3M | $4.1M | +4% |
| Costs & expenses | $406M | $396M | $10.3M | +3% |
| Pre-tax earnings | $88.0M | $61.6M | $26.4M | +43% |
| Other expense, net | $7.5M | $29.7M | −$22.3M | -75% |
| Cost of revenue | $217M | $211M | $6.0M | +3% |
| SG&A | $188M | $184M | $4.0M | +2% |
| Net earnings | $71.7M | $41.6M | $30.1M | +72% |
| Income tax | $16.2M | $20.0M | −$3.7M | -19% |
| Depreciation & amortization | $14.0M | $14.2M | −$154K | -1% |
| Share-based compensation | $10.1M | $9.6M | $542K | +6% |
| Working capital & other | $28.1M | $121M | −$92.7M | -77% |
| Operating cash flow | $124M | $186M | −$62.2M | -33% |
| Free cash flow (OCF − capex) | $97.1M | $166M | −$68.8M | -41% |
| Capital expenditures | $26.8M | $20.2M | $6.6M | +33% |
Questions
How much did Covista's revenue grow quarter over quarter in Q4 FY26?
Covista's revenue rose $14.4M (+3%) from $487M in Q3 FY26 to $501M in Q4 FY26.
What drove Covista's revenue change in Q4 FY26?
Walden +$24.3M (+13%); Chamberlain −$6.7M (-3%); Medical and Veterinary −$3.2M (-3%).